Molbio Diagnostics

Molbio Diagnostics is a pioneering molecular diagnostics company revolutionizing point-of-care testing (POCT) for infectious and non-communicable diseases. Molbio operates at the intersection of healthcare, biotechnology and artificial intelligence. The company specializes in portable, lab-grade diagnostic solutions designed to democratize access to advanced healthcare in low-resource and remote settings. For investors, Molbio offers exposure to scalable healthtech innovation with strong ESG alignment. Researchers and industry professionals will find its integration of AI, IoT, and decentralized testing a blueprint for equitable healthcare delivery.

Core Products & Services

• Truenat Platform: A WHO-endorsed, portable real-time PCR system enabling rapid, accurate diagnostics at the point of care.

• Truelab Quattro: A fully automated micro PCR analyzer performing 40–48 tests in 8 hours, even in primary healthcare centers.

• Digital Radiology & Pathology Solutions: Includes AI-powered portable X-rays (Prognosys) and cloud-based digital pathology (OptraSCAN).

• Comprehensive Test Menu: Over 40 assays for diseases like TB, COVID-19, HPV, dengue and antimicrobial resistance (AMR).

Unique Value Proposition

• Decentralized Diagnostics: Replaces centralized labs with portable, battery-operated devices requiring minimal infrastructure.

• Gold-Standard Accuracy: Delivers lab-grade PCR results in 60 minutes, enabling same-day diagnosis and treatment.

• Affordability: Tests cost a fraction of traditional lab prices, critical for low-income regions.

Business Model & Revenue Streams

1. Device Sales: Truenat PCR systems ($5,000–$10,000 per unit) sold to governments, NGOs and hospitals.

2. Reagent Kits & Cartridges: High-margin consumables for disease-specific testing (e.g., TB, COVID-19).

3. Subscription Services: Annual maintenance contracts (AMCs) for device upkeep and software updates.

4. Acquisition-Driven Expansion: Revenue from digital radiology (Prognosys) and pathology (OptraSCAN) verticals.

Customer Segmentation

• Governments & Public Health Programs: Primary buyers for TB/HIV elimination initiatives.

• Private Healthcare Providers: Hospitals and clinics in urban/rural areas.

• Global Health Organizations: Partnerships with WHO, Stop TB Partnership and UNICEF.

Growth Strategy

• Product Innovation: Expanding test menus (e.g., hepatitis, HPV) and integrating AI for predictive analytics.

• Global Market Penetration: Targeting Africa and Southeast Asia for TB/HIV diagnostics.

• Strategic Acquisitions: Enhancing capabilities in radiology (Prognosys) and digital pathology (OptraSCAN).

• IPO Plans: Filed for a ₹2,200–2,400 crore IPO (2025) to fund R&D and global expansion.